Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab vs tacrolimus in adult kidney transplant recipients (China seamless phase II/III)
CTR20260579Phase 3Active
- Sponsor
- Sanofi
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of frexalimab in kidney allograft rejection, sponsored by Sanofi. Started Mar 2026; status: active.
02
Drugs
frexalimab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on CTR20260579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260579.